Michael Higgins is an experienced biotechnology executive and is currently an entrepreneur-in-residence at Polaris Partners. Previously, he served as Chief Operating Officer and Chief Financial Officer at Ironwood Pharmaceuticals, Inc. from 2003 through 2014. In 2014, Mr. Higgins was named the Boston Business Journal’s CFO of the Year. Mr. Higgins worked at Genzyme Corporation from 1997 through 2003 in a variety of leadership roles, including Vice President of Corporate Finance and Vice President of Business Development. While at Genzyme, he was involved with multiple business units, including Cell Therapy, Gene Therapy and Orphan Diseases. Mr. Higgins also served as Chief Financial Officer of Procept, Inc. from 1992 to 1997. Mr. Higgins began his pharmaceutical career as a sales representative for Schering-Plough Corporation. Mr. Higgins is currently a board member of Genocea Biosciences, Inc. (Nasdaq: GNCA), Pulmatrix, Inc. (Nasdaq: PULM) and Private Equity Access Fund, II. Mr. Higgins holds a Bachelors of Science from Cornell University and a Masters of Business Administration from the Amos Tuck School of Business at Dartmouth College.

science